| |
|
Slide 1 :
|
By
James A. Yost, MD, MS, MBA
Emory Family Medicine Type II Diabetes |
|
|
Slide 2 :
|
OBJECTIVES:
INTRODUCTION
EPIDEMIOLOGY
GENETIC SUSCEPTIBILITY
PHYSIOLOGY
PATHOPHYSIOLOGY
SCREENING
DIAGNOSIS
COMPREHENSIVE DIABETES EVALUATION
MEDICAL NUTRITION THERAPY
GOALS OF THERAPY
TREATMENTS
Type II Diabetes |
|
|
Slide 3 :
|
Introduction:
Type 2 diabetes mellitus is characterized by hyperglycemia, insulin resistance, and relative impairment in insulin secretion
It is a common disorder with a prevalence that rises markedly with increasing degrees of obesity
Type II Diabetes |
|
|
Slide 4 :
|
Epidemiology:
Approximately 18.2 million individuals (6.3% of the US population), have diabetes
From 1990 to 1998, the prevalence increased 33%
The projected prevalence increase is165% by 2050
The economic burden attributable to diabetes was estimated to be $132 billion in 2002 Type II Diabetes |
|
|
Slide 5 :
|
Genetics:
2 – 6 times more prevalent in African Americans, Native Americans, Pima Indians, and Hispanic Americans in the United States than in whites
39% of patients have at least one parent with the disease
Among monozygotic twin pairs with one affected twin, approximately 90 percent of unaffected twins eventually develop the disease Type II Diabetes |
|
|
Slide 6 :
|
Physiology:
Type II Diabetes |
|
|
Slide 7 :
|
Type II Diabetes amylin Induces satiety |
|
|
Slide 8 :
|
Physiology:
GLP-1
Secreted by L-cells in the proximal small gut
Triggers satiety
Stimulates the pancreas to secrete insulin
Turns off glucagon
Prevents hypoglycemia
Degraded by DPP4
Amylin:
Second ß-cell hormone that is normally co-secreted with insulin in response to meals
Suppression of postprandial glucagon secretion
Decreases gastric emptying Type II Diabetes |
|
|
Slide 9 :
|
Pathophysiology:
Multifactorial process that occurs over an extended time
genetic
lifestyle
cultural
environmental factors
Obesity is the most common risk factor Type II Diabetes |
|
|
Slide 10 :
|
Screening:
Type II Diabetes |
|
|
Slide 11 :
|
Diagnosis:
FPG >126 mg/dL on 2 or more occasions
The presence of diabetic symptoms plus a casual plasma glucose concentration >200 mg/dL on 2 or more occasions
A 2-hr post load glucose >200 mg/dL during an OGTT (the glucose load should be 75 g anhydrous glucose dissolved in water) Type II Diabetes |
|
|
Slide 12 :
|
Diagnosis:
Impaired Fasting Glucose
FPG <100 mg/dL = normal fasting glucose
FPG from 100 to 125 mg/dL = impaired fasting glucose
FPG >126 mg/dL = provisional diagnosis of diabetes
Impaired Glucose Tolerance
2-hr 75-g OGTT <140 mg/dL = normal glucose tolerance
2-hr 75-g OGTT from 140 to 199 mg/dL = impaired
glucose tolerance
2-hr 75-g OGTT >200 mg/dL = provisional diagnosis of
diabetes Type II Diabetes |
|
|
Slide 13 :
|
Comprehensive Diabetes Evaluation:
Medical History
Symptoms
Eating patterns, nutritional status, and weight history
Exercise history
Medications
Risk factors for atherosclerosis
smoking, hypertension, obesity, dyslipidemia, and family history
Physical Examination
Head to toe
Must include monofilament exam Type II Diabetes |
|
|
Slide 14 :
|
Type II Diabetes |
|
|
Slide 15 :
|
Comprehensive Diabetes Evaluation:
Initial Laboratory Evaluation
Hemoglobin A1C
Fasting lipids
U/A
Microalbuminuria (yearly)
BUN/Cr (Yearly)
TSH (Yearly)
EKG (Yearly)
Anti-GAD antibodies (Once) (Type 1 DM)
C-peptide level (yearly for 5 years)
Every Visit Labs
FBS
A1C every 3 months or fructosamine every 2-3 weeks
U/A Type II Diabetes |
|
|
Slide 16 :
|
Comprehensive Diabetes Evaluation:
Referrals
Eye examination (yearly)
Medical Nutrition therapy (at lease once)
Podiatry (yearly) Type II Diabetes |
|
|
Slide 17 :
|
Type II Diabetes |
|
|
Slide 18 :
|
Type II Diabetes |
|
|
Slide 19 :
|
Medical Nutrition Therapy
Can achieve >2% reduction in A1C within the 1st year according to the United Kingdom Prospective Diabetes Study (UKPDS)
Type of CHO doesn’t matter, it’s the amount
1 CHO serving = 15 g CHO
Limit to 3-4 servings per meal, 1-2 servings per snack
Limit to 1800 to 2000 cal per day
Type II Diabetes |
|
|
Slide 20 :
|
Goals of Therapy Type II Diabetes |
|
|
Slide 21 :
|
Treatment:
Six classes of oral agents for treatment of type 2 diabetes
biguanides
sulfonylureas
meglitinides
Thiazolidinediones
alpha-glucosidase inhibitors
DPP-4 inhibitors
Two classes of non-insulin injections
Amylin analogs
GLP-1 analogs
Type II Diabetes |
|
|
Slide 22 :
|
Biguanides:
Actions: Decrease Gluconeogenesis and increases insulin sensitivity
Recommended initial medical therapy in almost all Type 2 pts.
Decrease A1C by 1-2.
Advantage: No hypoglycemia
Metformin (Glucophage):
500 mg PO q day then up to 1000 mg PO bid
Avoid use in situations where lactic acidosis is more likely.
Liver disease.
Renal insufficiency (Cr >1.5 male / Cr >1.4 female)
Type II Diabetes |
|
|
Slide 23 :
|
Sulfonylureas:
Increase insulin secretion by stimulating beta cell function of the pancreas
Decrease A1C by 1-2.
Glipizide (Glucotrol) 2.5 mg PO q day (start), 20 mg PO bid (max)
Glyburide (Micronase) 2.5 mg PO q day (start), 20 mg PO q day (max)
Glimepizide (Amaryl) 1 mg PO q AM 8 mg PO q day (max)
Biggest risk is hypoglycemia. Type II Diabetes |
|
|
Slide 24 :
|
Meglitinides
Similar but unrelated to sulfonyureas.
Increase insulin secretion by stimulating beta cell function of the pancreas
No distinct advantage, increased dosing frequency and increased cost
Short half life
Nateglinide (Starlix) 60 mg PO tid (before meals)
Repaglinide (Prandin) 0.5 mg PO tid (before meals)
Type II Diabetes |
|
|
Slide 25 :
|
Thiazodiolidinediones (TZD’s)
PPARg agonist. This action leads to increased insulin sensitivity in peripheral tissues.
A1C lowering of 1-1.5.
Pioglitazone (Actos) 15 mg PO q day (start), 45 mg PO q day (max)
Rosiglitazone (Avandia) 2 mg PO q day (start) 8 mg PO q day (max)
Advantage of class is ability to dose in renal insufficiency.
Disadvantages are increase in weight / increase peripheral edema / precipitate CHF / lower Hemoglobin / precipitate MI (not shown in randomized trial, but shown in recent meta analysis).
Type II Diabetes |
|
|
Slide 26 :
|
Alpha-glucosidase Inhibitors
Reduce absorption of carbohydrates.
A1C lowering is modest. 0.5 – 1.
Acarbose (Precose) 25 -50 mg PO tid (start) 100 mg PO tid (max)
Miglitol (Glyset) 25 mg PO tid (start) 100 mg PO tid (max)
Side effects limit effectiveness. Flatulence / Diarrhea.
Type II Diabetes |
|
|
Slide 27 :
|
DPP-IV Inhibitors
Dipeptidyl peptidase IV. Enzyme that deactivates GLP-1 and GIP.
A1C reduction of 0.5-1.0.
Sitagliptin (Januvia) 100 mg PO q day
Approved for Type 2 DM. Monotherapy or ideally as add on to metformin or TZD.
Advantages: Oral dosing
Disadvantages: Cost
Renal adjustment required.
Type II Diabetes |
|
|
Slide 28 :
|
Amylin analogs
A1C reduction 0.5-1.0
Pramlintide (Symlin) 60 mcg SQ q AC (start DM 2) (15 mcg if DM 1) 120 mcg SQ q AC, (max dose)(60 mcg if DM 1)
Only approved as add-on to insulin.
Advantages:
Mild weight loss.
No dose adjustment needed with kidney / liver dysfunction.
Can use in DM 1 or DM 2.
Disadvantages:
Nausea, usually resolves.
Hypoglycemia if insulin dose not adjusted
Decrease rapid acting insulin dose by 50% when starting pramlintide.
Type II Diabetes |
|
|
Slide 29 :
|
GLP-1 analogs
Slows gastric emptying
decreases post meal glucagon pulse
decrease appetite
A1C reduction of 1
Exenatide (Byetta)
5 mcg SQ bid up to 1 hour before AM and PM meals
10 mcg SQ bid up to 1 hour before AM and PM meals (max)
Advantages: Weight loss
Disadvantages: Nausea, cost, SQ dosing
Type II Diabetes |
|
|
Slide 30 :
|
Treatment
Insulin Therapy
Short acting insulins
regular (Humulin R)
lispro (Humalog)
aspart (NovoLog)
Glulisine (Apidra)
Long acting insulins
NPH insulin (Novolin N)
Detemir insulin (Levemir)
Glargine insulin (Lantus)
Inhaled insulin
Exubera
0.05 mg/kg inhaled tid (immediately prior to meals)
1 mg = 3 units regular insulin
3 mg = 8 units regular insulin
Type II Diabetes |
|
|
Slide 31 :
|
Insulin Therapy added to Oral Agents
When adding to oral agents, continue current dose but D/C sulfonylureas and decrease dose TZDs
Start basil bolus at approx. 10 units QHS
Increase dose by 2-3 units every 2-3 days to achieve FBS in AM of <110 mg/dl
Decrease dose by 2-3 units every 2-3 days if FBS <70 mg/dl Type II Diabetes |
|
|
Slide 32 :
|
Insulin Therapy Only
Best is basil plus prandial insulin
Determine total daily dose (TDD)
Start with 0.4 units/kg
Add 0.1 unit/kg for each of the following:
BMI > 40
New Diabetic with BG > 300
Known Diabetic with BG > 200
Subtract 0.1 unit/kg if > 75 y/o
If GFR 10-50, reduce TDD to 50% of calculated
If GFR <10, reduce TDD to 75% of calculated
Type II Diabetes |
|
|
Slide 33 :
|
A patient presents with symptoms of polyuria, polyphagia, and polydipsia.
Which of the following casual plasma glucose levels meets the criteria for a diagnosis of diabetes?
A. 111 mg/dL.
B. 134 mg/dL.
C. 152 mg/dL.
D. 183 mg/dL.
E. 200 mg/dL. Questions |
|
|
Slide 34 :
|
Because of the correlation between mean plasma glucose and hemoglobin (Hb) A1c levels, the American Association of Clinical Endocrinologists recommends an HbA1c goal of:
A. Less than 7.5%.
B. Less than 7%.
C. Less than 6.5%.
D. Less than 6%.
E. Less than 5.5%. Type II Diabetes |
|
|
Slide 35 :
|
You are establishing goals for diabetes control with an extremely motivated 39- year-old woman with type 2 diabetes. According to the American Association of Clinical Endocrinologists, the pre-prandial plasma glucose goal should be:
A. Less than 90 mg/dL.
B. Less than 100 mg/dL.
C. Less than 110 mg/dL.
D. Less than 120 mg/dL.
E. Less than 130 mg/dL. Type II Diabetes |
|
|
Slide 36 :
|
Which of the following oral antidiabetic agents does not cause hypoglycemia when given alone?
A. Metformin.
B. Acarbose.
C. Repaglinide.
D. Glyburide. Type II Diabetes |
|
|
Slide 37 :
|
Which of the following antihypertensive drugs is recommended for reducing the progression to macroalbuminuria in a patient with diabetes?
A. Angiotensin receptor blocker.
B. Thiazide diuretic.
C. Beta blocker.
D. Calcium channel blocker. Type II Diabetes |
|
|
Slide 38 :
|
According to the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), a 41-year-old patient with diabetes, who does not have coronary artery disease, should be treated to a low-density lipoprotein cholesterol goal of:
A. Less than 200 mg/dL.
B. Less than 150 mg/dL.
C. Less than 100 mg/dL.
D. Less than 70 mg/dL.
E. Less than 50 mg/dL. Type II Diabetes |
|
|
Slide 39 :
|
American Diabetic Association. Diabetic care 2007;31 (S1)
Diabetes Prevention Program Research Group. N. Eng J Med 2002;346:393
American Association of Clinical Endocrinologist www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf
American Academy of Family Physicians www.aafp.org/online/en/home/cme/selfstudy/videocme/diabetes.html
Association of Family Medicine Residency Program directors Frontline Diabetic Workshop
References |
|